Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5431677 | 0.84 | PTGS1 (0.53) | PTGS2PTGS1KMT2AMEN1GAA | |
| SCHEMBL28225375 | 0.81 | PTGS2 (0.58) | PTGS2PTGS1KMT2AMEN1GAA | |
| SCHEMBL11210113 | 0.77 | KMT2A (0.56) | PTGS2PTGS1KMT2AMEN1GAA | |
| SCHEMBL2407274 | 0.75 | BRD4 (0.43) | PTGS2PTGS1KMT2AMEN1CYP3A4 | |
| SCHEMBL2205047 | 0.75 | PTGS1 (0.68) | PTGS2PTGS1KMT2AMEN1GAA | |
| SCHEMBL6380887 | 0.75 | PTGS2 (0.58) | PTGS2PTGS1KMT2AMEN1GAA | |
| SCHEMBL10860093 | 0.74 | MEN1 (0.40) | KMT2AMEN1GAACA12CA1 | |
| SCHEMBL635055 | 0.71 | MAPT (0.39) | CYP3A4MAPTBRD4BRD2POLB | |
| SCHEMBL10780275 | 0.71 | ALDH1A1 (0.58) | PTGS2PTGS1KMT2AMEN1GAA | |
| SCHEMBL2277199 | 0.70 | PTGS2 (1.00) | PTGS2PTGS1KMT2AMT-CO2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106414458-B | Novel fused imidazobenzothiazole compounds | TORRENT PHARMACEUTICALS LTD. (IN) | 2019-10-29 | — | — | CN | disclosed |
| US-10227361-B2 | Fused imidazobenzothiazole compounds | TORRENT PHARMACEUTICALS LIMITED (IN) | 2019-03-12 | — | — | US | disclosed |
| EP-3122755-B1 | NOVEL FUSED IMIDAZOBENZOTHIAZOLE COMPOUNDS | TORRENT PHARMACEUTICALS LTD (IN) | 2018-11-07 | — | — | EP | disclosed |
| US-20180127437-A1 | NOVEL FUSED IMIDAZOBENZOTHIAZOLE COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2018-05-10 | — | — | US | disclosed |
| US-9908898-B2 | Fused imidazobenzothiazole compounds | TORRENT PHARMACEUTICALS LIMITED (IN) | 2018-03-06 | — | — | US | disclosed |
| US-20170107233-A1 | NOVEL FUSED IMIDAZOBENZOTHIAZOLE COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2017-04-20 | — | — | US | disclosed |
| EP-3122755-A1 | NOVEL FUSED IMIDAZOBENZOTHIAZOLE COMPOUNDS | Torrent Pharmaceuticals Limited (IN) | 2017-02-01 | — | — | EP | disclosed |
| WO-2015145336-A1 | NOVEL FUSED IMIDAZOBENZOTHIAZOLE COMPOUNDS | TORRENT PHARMACEUTICALS LIMITED (IN) | 2015-10-01 | — | — | WO | disclosed |
| US-8754107-B2 | Aminopyrrolidines as chemokine receptor antagonists | ABBVIE INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8569295-B2 | Bicyclic urea compounds | MERCK PATENT GMBH (DE) | 2013-10-29 | — | — | US | disclosed |
| WO-2007121920-A2 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2007-11-01 | — | — | WO | disclosed |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-25 | — | — | US | disclosed |
| EP-1813606-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-08-01 | — | — | EP | disclosed |
| EP-1812383-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | Smithkline Beecham Corporation (US) | 2007-08-01 | — | — | EP | disclosed |
| WO-2007004749-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | WO | disclosed |
| EP-1622610-B1 | 1-(2H-PYRAZOL-3-YL)-3-{4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | AVENTIS PHARMA INC (US) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006052722-A1 | GLYCOGEN PHOSPHORYLASE INHIBITOR COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-23 | — | — | US | disclosed |
| EP-1622610-A1 | 1-(2H-PYRAZOL-3-YL)-3- 4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL -UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | Aventis Pharmaceuticals Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004100946-A1 | 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127437-A1 | NOVEL FUSED IMIDAZOBENZOTHIAZOLE COMPOUNDS | CYP3A5, CYP11B2, CYP3A4 | PTGS2 432/4885PTGS1 1493/4885KMT2A 3688/4885 |
| US-20070249670-A1 | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof | PYGM, PYGL, GYS1 | PTGS2 1207/4885PTGS1 682/4885KMT2A 4148/4885 |
| US-10227361-B2 | Fused imidazobenzothiazole compounds | IPO4, CYP3A5, CYP3A4 | PTGS2 1006/4885PTGS1 2090/4885KMT2A 3864/4885 |
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | TNF, LITAF, MAPK1 | PTGS2 273/4885PTGS1 85/4885KMT2A 4746/4885 |
| US-20170107233-A1 | NOVEL FUSED IMIDAZOBENZOTHIAZOLE COMPOUNDS | CYP3A5, CYP11B2, CYP3A4 | PTGS2 432/4885PTGS1 1493/4885KMT2A 3688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.